Abstract
BackgroundBiologic drugs such as adalimumab, etanercept, and infliximab represent major first-line and second-line treatments for rheumatoid arthritis (RA) patients. However, their high cost poses a massive burden on healthcare systems worldwide. The expiration of patents for these biologics has driven the production of biosimilar drugs, which are potentially less costly and remarkably similar, albeit not identical to the reference molecules. This paper aims to outline the protocol of a systematic review that will investigate the efficacy and safety profile of biosimilars compared to biologics (objective 1) and the impact of switching between biosimilar drugs and reference biologics on the management of RA patients (objective 2).MethodsWe will investigate the effects of any biosimilars of adalimumab, etanercept, and infliximab on RA patients. We will include randomized controlled trials (RCTs) or quasi-RCTs to assess efficacy and safety outcomes and RCTs with two- or multiple-part designs to evaluate the consequences of switching from reference biologics to biosimilar drugs (and vice-versa). Electronic searches will be performed through MEDLINE (via PubMed), EMBASE, LILACS, and CENTRAL (from inception to April 2021). Two independent reviewers will screen studies, extract data, and evaluate the risk of bias. The latter will be carried out considering specific domains from equivalence trials and switching studies. Random-effects models will be fitted to obtain summary estimates using either relative risk or standardized mean difference as a metric. The primary outcome will be the rate of treatment success according to the American College of Rheumatology 20 (ACR20), and the co-primary outcome will be the Health Assessment Questionnaire—Disability Index (HAQ-DI). Conclusions will be based on equivalence hypothesis testing using predefined margins of equivalence elicited from a group of experienced rheumatologists and prior studies. The overall certainty of the evidence will be assessed based on the GRADE system.DiscussionThe present investigation proposes a comprehensive, clinician-oriented approach to assess the equivalence and the impact of switching between biosimilars and biologics on the management of patients with RA. Our results will elucidate the efficacy, safety, immunogenicity of biosimilars, and the clinical consequences of substituting biologics with biosimilars in the management of RA.Systematic review registrationPROSPERO CRD42019137152 and CRD42019137155
Highlights
Biologic drugs such as adalimumab, etanercept, and infliximab represent major first-line and secondline treatments for rheumatoid arthritis (RA) patients
Biologics pose an important challenge for the sustainability of healthcare systems worldwide, given the high direct costs associated with this drug category [1]
We describe the protocol of a systematic review that will address the efficacy, safety, and immunogenicity of biosimilars compared to biologics, and the impact of switching between biosimilar drugs and reference biologics on the management of RA patients
Summary
Biologic drugs such as adalimumab, etanercept, and infliximab represent major first-line and secondline treatments for rheumatoid arthritis (RA) patients. Their high cost poses a massive burden on healthcare systems worldwide. Rheumatoid arthritis (RA) is a chronic inflammatory joint disease that affects up to 20 million people worldwide, thereby representing a major public health burden with important socioeconomic consequences [1,2,3]. Synthetic disease-modifying antirheumatic drugs (DMARDs) are the first line of therapy and associated with biologic DMARDs have changed clinical outcomes, reducing the inflammatory burden of disease and, chronic articular deterioration [4]. Biologics pose an important challenge for the sustainability of healthcare systems worldwide, given the high direct costs associated with this drug category [1]. Expenses related to biologic treatments can represent almost 40% of the net drug spending in the USA [12]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
